Menu
Fechar
HRS4R
Vull donar
Firma
JOAQUIM BOSCH-BARRERA
Posició
Investigador/a Consolidat - R3
Investigador/a Consolidat - R3
Projectes
Publicacions
Propietat intel·lectual

Projectes

Oncologia de Precisió de Girona

Estudi "Organ specific biomarkers and therapies to improve the management of brain metastasis".

Codi oficial: La Marató 201906-30 Data inici: 30/09/2020 Data fi: 29/09/2023 Investigador/a principal: JOAQUIM BOSCH BARRERA Organisme finançador: FUNDACIO LA MARATO TV3 Ajuda: 109,562.50 €
Oncologia de Precisió de Girona

A therapeutic strategy to co-target brain metastasis-initiating and hyperlipidemia-driving mechanisms in lorlatinib-treated NSCLC

Codi oficial: Pfizer 2019 Joaquim Bosch Data inici: 05/07/2019 Data fi: 30/06/2023 Investigador/a principal: JOAQUIM BOSCH BARRERA Organisme finançador: PFIZER, S.L.U. Ajuda: 97,750 €
Genètica Cardiovascular

Data-driven cancer genome interpretation for personalised cancer treatment

Codi oficial: 101057509 Data inici: 01/11/2022 Data fi: 31/10/2027 Investigador/a principal: RAMON BRUGADA TERRADELLAS Organisme finançador: EUROPEAN COMISSION Ajuda: 218,975 €
Oncologia de Precisió de Girona

Identification of biomarkers in liquid biopsy related to tumor microenvironment of brain metastases from lung cancer patients treated with brain radiotherapy and / or immunotherapy

Codi oficial: Tumor microenvironment of brain metastases Data inici: 01/12/2022 Data fi: 30/11/2025 Investigador/a principal: JOAQUIM BOSCH BARRERA Organisme finançador: ASSOCIACIÓ ESPANYOLA CONTRA EL CÀNCER Ajuda: 105,000 €

Publicacions

Karachaliou N, Codony-Servat J, Teixidó C, Pilotto S, Drozdowskyj A, Codony-Servat C, Giménez-Capitán A, Molina-Vila MA, Bertrán-Alamillo J, Gervais R, Massuti B, Morán T, Majem M, Felip E, Carcereny E, García-Campelo R, Viteri S, González-Cao M, Morales-Espinosa D, Verlicchi A, Crisetti E, Chaib I, Santarpia M, Luis Ramírez J, Bosch-Barrera J, Felipe Cardona A, de Marinis F, López-Vivanco G, Miguel Sánchez J, Vergnenegre A, Sánchez Hernández JJ, Sperduti I, Bria E, Rosell R

Author Correction: BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer.

SCIENTIFIC REPORTS, 2023, 13, 3620-3620 dx.doi.org/10.1038/s41598-023-30374-9

Bosch-Barrera J, Roqué A, Teixidor E, Carmona-Garcia MC, Arbusà A, Brunet J, Martin-Castillo B, Cuyàs E, Verdura S, Menendez JA

Clinical Management of COVID-19 in Cancer Patients with the STAT3 Inhibitor Silibinin

Pharmaceuticals, 2022, 15 dx.doi.org/10.3390/ph15010019
0

Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism

NATURE MEDICINE, 2022, 28, 752-765 dx.doi.org/10.1038/s41591-022-01749-8
0

Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics

Bmc Cancer, 2022, 22, 732-732 dx.doi.org/10.1186/s12885-022-09830-8
0

Silibinin Suppresses the Hyperlipidemic Effects of the ALK-Tyrosine Kinase Inhibitor Lorlatinib in Hepatic Cells

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 dx.doi.org/10.3390/ijms23179986
0

Molecular Divergence upon EGFR-TKI Resistance Could Be Dependent on the Exon Location of the Original EGFR-Sensitizing Mutation

Cancers, 2022, 14 dx.doi.org/10.3390/cancers14184446
0

Safety and Efficacy of Dostarlimab in Patients With Recurrent/Advanced Non-small Cell Lung Cancer: Results from Cohort E of the Phase I GARNET Trial.

CLINICAL LUNG CANCER, 2022, 23, 415-427 dx.doi.org/10.1016/j.cllc.2022.05.013
0

AZ12756122, a novel fatty acid synthase inhibitor, decreases resistance features in EGFR-TKI resistant EGFR-mutated NSCLC cell models.

BIOMEDICINE & PHARMACOTHERAPY, 2022, 156, 113942-113942 dx.doi.org/10.1016/j.biopha.2022.113942
0

Silibinin Overcomes EMT-Driven Lung Cancer Resistance to New-Generation ALK Inhibitors

Cancers, 2022, 14 dx.doi.org/10.3390/cancers14246101

Riudavets, M, Auclin, E, Mosteiro, M, Dempsey, N, Majem, M, Lobefaro, R, Lopez-Castro, R, Bosch-Barrera, J, Pilotto, S, Escalera, E, Tagliamento, M, Mosquera, J, Zalcman, G, Aboubakar-Nana, F, Ponce, S, Dal Maso, A, Spotti, M, Mielgo-Rubio, X, Mussat, E, Reyes, R, Benitez, JC, Lupinacci, L, Duchemann, B, De Giglio, A, Blaquier, J, Audigier-Valette, C, Scheffler, M, Nadal, E, Lopes, G, Signorelli, D, Garcia-Campelo, R, Menis, J, Bluthgen, V, Campayo, M, Recondo, G, Besse, B, Planchard, D, Mezquita, L

Original Research Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations

EUROPEAN JOURNAL OF CANCER, 2022, 167, 142-148 dx.doi.org/10.1016/j.ejca.2022.02.014

Propietat intel·lectual

Joaquim Bosch Barrera

MEANS FOR PREVENTING AND TREATING BRAIN METASTASIS

Número de publicació: EP20170382891 Data de publicació: 2019-06-26

Formulari de contacte

Coneix l’IDIBGI!

 menu